Ukraine pharma reps meet with Health Minister on strategic proposals

17 March 2014

Earlier this month, there was a meeting between Ukraine Ministry of Health Oleh Musiy and the board of the Association of Pharmaceutical Research and Development (APRaD), as well as the Health Care Committee of American Chamber of Commerce in Ukraine, when representatives of the international pharmaceutical industry proposed specific tactical and strategic proposals to the MoH for the first three months.

Tactical suggestions focussed on the following issues:

Sources of uninterrupted access to medicines for patients under governmental programs, in particular through the conclusion of long term “price-volume agreements” with producers, which is common practice in Europe.
Transparent tender system, namely the transition to electronic trading systems which will provide transparency and thus save budget.
Regulatory initiatives to improve access to medicines and to reduce prices: a) simplification of state registration of medicinal products registered by the EMA (European Medicines Agency) centralized procedure; b) cancellation of re-registration; c) protection of intellectual property rights.
Equal rights and rules for market participants. Specifically, the aim is to eliminate any preferences that limit patient access to needed care and/or can potentially damage the patients’ health. Also, this will review pilot projects to improve access to medicines with proven effectiveness. Implementation of reimbursement system under the Insulin Pilot Project.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >